24-26 April, 2018
Amsterdam

Download the Event Guide

Speakers

Expand/Collapse

Eustache Paramithiotis
Vice-President, Discovery
Caprion Biosciences Inc

An innovative, experienced multidisciplinary scientist with formal training in immunology and expertise in oncology, infectious and metabolic disease, Dr. Paramithiotis has been responsible for novel target and biomarker discovery applications and also leads the development of Caprion’s privately and publicly funded biomarker discovery programs. Dr. Paramithiotis holds a PhD in Immunology from McGill University and did post-doctoral research in immune system development and memory at the Howard Hughes Medical Institute at the University of Alabama at Birmingham.

Day One

Wednesday 25th April, 2018

14.15 | Identification and Characterization of Presented Tumour Neo-Epitopes from Metastatic Colon Cancer

Jim Johnston
Executive Director, Inflammation
Amgen

Jim Johnston is Executive Director of Research at Amgen with responsibility for Inflammation and Immuno-Oncology. He made a number of key discoveries – including the identification and characterization of JAK3 and work which outlined its importance in autosomal SCID. He was awarded the Most Valuable Scientist award at the BRMP, NIH (1996), the Hajime Award at DNAX, (1999) and the Irish Society of Immunology RDS Public Lecture Award (2010). He founded and was Chief Scientist at Fusion Antibodies Ltd, a company that develops humanized monoclonal antibody therapeutics.  At Amgen his group are responsible for the development of nine drugs now in clinical development. He has 15 patents and has >130 peer reviewed manuscripts.

Day One

Wednesday 25th April, 2018

11.45 | Panel: Determining Best Practices for Neoantigen Prediction

Martin Löwer
Head of Bioinformatics
TRON

Martin Löwer, PhD is a computational biologist heading the Bioinformatics department of TRON (Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH), focusing on translational research in cancer immunotherapy and biomarker development. His expertise includes next-generation sequencing data analysis, cancer genomics, machine learning and algorithm design. Previously, he has worked as computational biologist at the Goethe University Frankfurt, applying structure based virtual screening to targets of human pathogens and as a software consultant for Merz Pharma, Frankfurt.

Day One

Wednesday 25th April, 2018

11.45 | Panel: Determining Best Practices for Neoantigen Prediction

11.15 | Overcoming Neoantigen Prediction Challenges in Clinical Application

Andrea van Elsas
CSO
Aduro Europe

Andrea van Elsas became Chief Scientific Officer (CSO) in September 2017, following his tenure as Chief Scientific Officer of Aduro Biotech Europe since November 2015. Prior to its acquisition by Aduro in 2015, Dr. Andrea van Elsas co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology. From 1999 to 2011, he held numerous positions at Organon in Oss, The Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), and as the Director of Tumor Immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab. As a postdoctoral researcher from 1997-1999, Andrea worked at the University of California, Berkeley, studying antibodies blocking CTLA-4 for the treatment of cancer and is a co-inventor on the original patents that formed the basis for the development of Yervoy® (ipilimumab), the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma.

Day Two

Thursday 26th April, 2018

11.45 | Panel: Maximizing the Potential of Neoantigen-based Targeting for Cancer Vaccines

09.45 | Live-Attenuated Double Deleted Listeria Monocytogenes (pLADD) Immunotherapy Targeting MSS CRC

Matthias Miller
Senior Project Manager
BioNTech

Matthias Miller started to work as a clinical project manager for the BioNTech AG (Mainz, Germany) in August 2014. He is managing the first-in-human clinical trial utilizing polytopic RNA-vaccines targeting mutation-derived neo-antigens. Currently, he focuses on projects that aim at taking the next steps in the clinical development of this personalized vaccine and investigates the implementation of novel technologies into the manufacturing process.

Day Two

Thursday 26th April, 2018

14.45 | Panel: Advancing Manufacturing Practices for Personalized Cancer Vaccines

11.45 | Panel: Maximizing the Potential of Neoantigen-based Targeting for Cancer Vaccines

09.15 | Reinvigorating Cancer Vaccines with Neoantigen Targeting Individualised mRNA-based Vaccines for the Treatment of Cancer

Agnete Fredriksen
CSO
Vaccibody

Agnete B. Fredriksen is Founder and Chief Scientific Officer of Vaccibody AS. She holds a M.Sc., Ph.D. from Institute of Immunology, University of Oslo, Rikshospitalet in Norway where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies. She has co-authored a range of scientific papers and is inventor on several patents with a focus on vaccine development and immunotherapy. She is in charge of the preclinical development of neoantigen-based vaccines at Vaccibody aiming for first clinical trials in 2017.

Day Two

Thursday 26th April, 2018

14.45 | Panel: Advancing Manufacturing Practices for Personalized Cancer Vaccines

14.15 | Individualised Cancer Neoantigen Vaccines: How can we Make it a Viable Product?

Hyewon Phee
Senior Scientist & Project Manager, Inflammation
Amgen

I started my career in academia as a T cell immunologist, then made a transition to pharmaceutical Industry at Amgen in 2015. Prior to joining Amgen, I was trained in the laboratory of Dr. Art Weiss at UCSF as a postdoctoral fellow and continued my research as an Assistant Adjunct Professor at UCSF. In 2012, I moved to Chicago to lead a research lab as a tenure-track Assistant professor at Northwestern University. In 2015, I joined Amgen to pursue a target discovery research in Inflammation and Oncology. My interest in T cell activation in the field of Inflammation and Cancer fits perfectly with Cancer Vaccination research program at Amgen and I feel very fortunate to be a part in Neoantigen Cancer Vaccination community.

Day One

Wednesday 25th April, 2018

15.45 | Immunogenicity of Neoantigen Cancer Vaccines

Heinz Lubenau
COO
VAXIMM GmbH

Heinz Lubenau co-founded VAXIMM in 2008 and has been responsible for all development activities since then. Prior to this, 2003-2008, he was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX, where he led the development work of the first biosimilar G-CSF Ratiograstim® from preclinical studies through European marketing approval and launch and of the 2nd generation G-CSF Lonquex from project implementation to clinical Phase 2. In 1994 he joined Servier in Munich and became Clinical Research Manager and Project Director Internal Medicine in 2001. Heinz Lubenau gained his PhD in pharmacy from Johannes-Gutenberg-University, Mainz.

Day Two

Thursday 26th April, 2018

14.45 | Panel: Advancing Manufacturing Practices for Personalized Cancer Vaccines

11.15 | Fast and Cost-Effective Oral Delivery Technology of Personalized T-Cell Vaccines Based on a Live Attenuated Bacteria Platform

Sean Michael Boyle
Director, Bioinformatics Applications
Personalis

Day One

Wednesday 25th April, 2018

12.15 | From Sample to Neoantigens for Vaccines: Key Challenges and Solutions

Toni Weinschenk
Founder & CTO
Immatics Biologics

Since more than fifteen years, Dr Toni Weinschenk is active in the field of cancer immunology with focus on discovery of HLA-presented peptides from native tumor and normal tissues by mass spectrometry. He is regarded the world’s leading expert in ultra-high sensitive, quantitative and high-throughput mass spectrometry of HLA ligands. Toni Weinschenk co-founded Immatics Biotechnologies GmbH during his PhD studies and is the creator of the XPRESIDENT® target discovery engine for identification, selection and validation of TUMAPs (tumor-associated peptides) as therapeutic cancer vaccines as well as targets for antibody-, T-cell-receptor-based and cellular approaches. At Immatics Biotechnologies GmbH, Toni Weinschenk heads the Discovery Department with approx. 20 FTEs dedicated to target discovery and validation. At Immatics US Inc., his role as Chief Technology Officer is to setup and run Immatics’ target discovery capabilities as biomarkers for clinical trials conducted in Houston, TX. Toni Weinschenk studied biochemistry in Tuebingen and at the Max-Planck-Institute in Munich, Germany. His passion for HLA ligands and ligandomes developed during his PhD thesis in the lab of Hans-Georg Rammensee. Toni Weinschenk is inventor on many patents and co-authored publications in the cancer immunology field in peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Immunological Reviews and Cell Reports.

Day Two

Thursday 26th April, 2018

11.45 | Panel: Maximizing the Potential of Neoantigen-based Targeting for Cancer Vaccines

10.45 | Personalised Onco-Immunotherapy: in vivo and ex vivo Vaccination Trials

Michal Bassani-Sternberg
Immunopeptidomics Unit, Center of Experimental Therapeutics, Department of Oncology
UNIL/CHUV

Michal Bassani-Sternberg is heading the Immunopeptidomics unit that is integrated within the Center of Experimental Therapeutic (CTE) in the department of Oncology at the CHUV, Lausanne, Switzerland, where she integrates mass spectrometry based immunopeptidomics into the innovative translational clinical strategy of personalized immunotherapy. In the last ten years, Dr Bassani-Sternberg has focused her research mainly on the development of methodologies for highly accurate and in-depth immunopeptidomics. She has completed her PhD at the Faculty of Biology at the Technion - Israel Institute of Technology and post-doctorate at the Proteomics and Signal Transduction Department, headed by Prof. Matthias Mann at the Max Planck Institute of Biochemistry. Recently she has integrated next generation sequencing with immunopeptidomics to directly identify patient’s specific neo-epitopes presented on melanoma tissues.

Day One

Wednesday 25th April, 2018

11.45 | Panel: Determining Best Practices for Neoantigen Prediction

08.45 | Immunopeptidomics: Accelerating the Development of Personalised Cancer Immunotherapy - How can we Improve Identification and Prioritisation of Neoantigens with MS Based Immunopeptidomics?

Morten Nielsen
Professor,  Group leader Immunoinformatics and Machine-Learning, Department of Bio and Health Informatics,
The Technical University of Denmark

Morten Nielsen holds a shared position as Professor of Bioinformatics at the Department of Systems Biology, at the Technical University of Denmark, and the Universidad Nacional de San Martin, Argentina. MN graduated with a master in physics from the University of Copenhagen. Obtained his PhD (also in physics) from the University of McGill, Canada. The core of Morten Nielsen’s research deals with the development of novel and advanced data-driven prediction methods for pattern recognition in biological systems. Morten Nielsen is a pioneer in the field of immunological bioinformatics and a key inventor of several state-of- the-art methods for T and B cell epitope discovery. He has been a partner in several large epitope discovery grants and has published numerous articles and book chapters within the fields of immunology, immunological bioinformatics and neural networks.

Day One

Wednesday 25th April, 2018

09.15 | Advances in the Field of In-silico Methods for the Identification of Neoepitopes

Sebastiano Battaglia
Assistant Professor of Oncology, Centre of Immunotherapy
Roswell Park Cancer Centre

I come from a background in transcriptional regulation, genetics and bioinformatics and I work on merging together those complementary disciplines with final goal of developing neoantigen specific immunotherapies for patients with ovarian cancer. The focus of my lab is to exploit the genetic characteristics of tumor cells by combining bioinformatics and molecular biology approaches. We aim to develop translational approaches that can be used in the clinic to improve current standard of care and ultimately offer potent therapeutic opportunities to cancer patients.

Day One

Wednesday 25th April, 2018

13.45 | Optimising the Neoantigenic Landscape in Low Mutational Burden Tumours for Optimal T Cells Response

Nadine Defranoux
Program Manager
Parker Institute for Cancer Immunotherapy

Dr. Nadine Defranoux is currently a Program manager at the Parker Institute for Cancer Immunotherapy (PICI), a non-profit institute focused on accelerating breakthrough research in immuno-oncology.  Dr. Defranoux joined PICI in 2016 and leads the Tumor neoantigEn SeLection Alliance (TESLA), a joint initiative with the Cancer Research Institute (CRI) aimed at optimizing approaches to identify actionable immunogenic neoantigens. She has a significant expertise and experience in leading collaborative research programs with pharma and academic groups in areas of inflammation, infectious diseases and cancer.

Day One

Wednesday 25th April, 2018

11.45 | Panel: Determining Best Practices for Neoantigen Prediction

Alexandre Harari
Professor
CHUV

After a decade in the anti-pathogen immunity field where he was a pioneer in the association between T-cell polyfunctionality and immune signatures of effective control, Dr. Harari joined the Department of Oncology, in Lausanne Switzerland, in 2014. He is currently team leader in the Antigen Discovery Unit, Director of the Immune Monitoring and T-cell discovery Core and Associate Director of the Center of Experimental Therapeutics. He is currently developing methodologies for the development of personalized immunotherapy. Dr. Harari is author of more than 60 peer-reviewed publications and the recipient of several awards.

Day One

Wednesday 25th April, 2018

15.15 | Sensitive Identification and Functional Profiling of Neoepitopespecific T Cells

Stephen Johnston
Director, Centre for Innovations in Medicine, Biodesign Institute
Arizona State University

Dr. Johnston directs the Center for Innovations in Medicine (CIM) at the Biodesign Institute.  CIM is unique in its focus on inventing disruptive technologies in biomedicine. The mission is to contribute to the transformation of medicine through technologies that allow prevention, early detection and new therapeutic treatment of disease.  Toward this goal CIM is focusing on developing three of his inventions. One project is to create a universal, preventative cancer vaccine. A second is to develop a system for continuous, comprehensive, cheap health monitoring.  The third is based on an invention for making new therapeutics and targeted anti-infectives. Johnston largely focuses on invention. He was inventor/ co-inventor of pathogen derived resistance, mitochondrial transformation, TEV protease system, the gene gun, gene immunization, expression library immunization, linear expression elements, synbodies and immunosignaturing. He was professor and director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University before moving to ASU. He was co-founder of Eliance (now Macrogenics), HealthTell and Calviri.  

Day Two

Thursday 26th April, 2018

13.45 | A New Source of Highly Immunogenic Neoepitopes for Cancer Vaccines

Trevor Clancy
Co-Founder & CSO
Oncolmmunity

Day One

Wednesday 25th April, 2018

09.45 | An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens